Skip to main content

A novel approach to non-invasive and personalized skin cancer diagnosis

Project description

Revolutionising skin cancer diagnostics

French company DAMAE Medical is developing new dermatological diagnostics based on a disruptive line-field confocal optical coherence tomography technology in a hand-held imaging device. The device captures in situ images of the skin layers with cellular resolution. It provides accurate diagnosis, thus minimising biopsies of benign lesions and improving detection of melanoma and non-melanoma skin cancers. Simultaneously, DAMAE is developing software to assist dermatologists with image interpretation and for telepathology and patient services. The company has completed the feasibility phase, resulting in a prototype of the technology and a consolidated atlas of skin cancer clinical images. The main objective of current phase 2 of the EU-funded OCTAV project is to achieve market assessment, clinical validation and regulatory approval.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

DAMAE MEDICAL
Net EU contribution
€ 2 400 000,00
Address
Batiment 503 - Campus Scientifique D'orsay
91400 Orsay
France

See on map

Region
Ile-de-France Ile-de-France Essonne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 085 857,00